SlideShare a Scribd company logo
GLYCAN STRUCTURAL ANALYSIS THROUGHOUT
BIOTHERAPEUTIC DEVELOPMENT
Dr Richard Easton
Team Leader Carbohydrate AnalysisTeam Leader, Carbohydrate Analysis
SGS Life Science Services
Wokingham, UK
 What is glycosylation? What is glycosylation?
 What aspects of glycosylation are key? What aspects of glycosylation are key?
H th b i ti t d? How can these be investigated?
2
N GLYCOSYLATIONN-GLYCOSYLATION
 Attached to Asn in the consensus Attached to Asn in the consensus
sequence …Asn-X-Ser/Thr…where X is
any AA except Pro
 Initiated in ER by en bloc transfer of a pre-
formed lipid-anchored conserved glycan
 Mature glycans formed by trimming (in ER
and Golgi) and elongation (Golgi)
 Found on mammalian, insect, fungal,
bacterial and plant cell proteins
3
O GLYCOSYLATIONO-GLYCOSYLATION
 Occurs on Ser and ThrOccurs on Ser and Thr
 No consensus sequence but some “rules” eg nearby proline,
tandem repeats of Ser/Thr
 Initiated in Golgi by addition of a single sugar - usually GalNAc in
mammals
 Additi l dd d ti ll t f th Additional sugars are added sequentially to form the core
sequence and then the antennae
 Cores 1 & 2 are very common in many glycoproteinsy y g y p
 Other monosaccharides may act as linkers depending on the
protein structure eg O-linked Fucose in EGF domains
 Cores 1 & 2 are very common in many glycoproteins
 Found on mammalian, insect, fungal, bacterial and plant cells
4
MONOSACCHARIDE STRUCTURESMONOSACCHARIDE STRUCTURES
5
EUKARYOTIC N GLYCAN BIOSYNTHESISEUKARYOTIC N-GLYCAN BIOSYNTHESIS
6
IN YEAST HIGH MANNOSE GLYCANS ARE MADE
LARGER BY POLYMANNOSYLATIONLARGER BY POLYMANNOSYLATION
7
PLANTS AND INVERTEBRATES DECORATE THE
N-GLYCAN CORE IN MORE DIVERSE WAYS THAN
MAMMALS
8
N-GLYCOSYLATION IN FISH AND BIRDSN-GLYCOSYLATION IN FISH AND BIRDS
some fish glycans are the most
decorated of all known glycans
9
decorated of all known glycans
SELECTED MAMMALIAN N GLYCAN STRUCTURESSELECTED MAMMALIAN N-GLYCAN STRUCTURES
(i)
(iii)
(ii)
Erythropoietin
Glycodelin S
Gl d li A
(iv)
(v)
+/-
(vi)
Glycodelin A
+/-
Tamm-Horsfall glycoprotein
M kid
Neutrophil
10
Mouse kidney
O LINKED OLIGOSACCHARIDES CORES 1 AND 2O-LINKED OLIGOSACCHARIDES CORES 1 AND 2
11
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
12
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
13
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
14
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
15
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
16
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
17
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
18
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
19
ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS
20
MONOSACCHARIDE ANALYSIS – BOVINE FETUINO OS CC S S O U
 Is my molecule glycosylated?
• Is the glycosylation N linked and if so what type (complex high mannose)?M-Scan Ltd.
Sample: Fetuin standard
Job: 12849 Sample No:Acquired on: 29-Sep-2000 at 13:37:38 by:
100
%
FETST299 Scan EI+
298
6.30e4
21.83
N-Acetyl
neuraminic acid
• Is the glycosylation N-linked and if so what type (complex, high mannose)?
• Is there evidence of O-glycosylation?
 Is there evidence of carbohydrate contamination coming through the process?
• High levels of glucose may indicate breakdown of, for example, gel filtration beads
100
0
%
FETST299 Scan EI+
173
1.56e5
16.98
N-Acetyl
g g y , p , g
100
0
%
16.38 21.83
17.13
FETST299 Scan EI+
20411.32 Galactose
N-Acetyl
galactosamine
y
glucosamine
0
100
%
3.69e512.08
12.65 13.12
13.48 16.98 21.83
FETST299 Scan EI+
Mannose
Galactose
Glucose
100
%
FETST299 Scan EI+
TIC
3.99e6
10.28
7.72
7.00
21.83
11.32
12.08
11.47
16.98
13.12
12.65
13.50
Arabitol (IS)
21
8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00
Time0
7.72
DMB SIALIC ACID ANALYSISDMB SIALIC ACID ANALYSIS
Neu5Ac Neu5Gc
Sialic acid reference panel
Neu5,9Ac2
Neu5,7Ac2
Neu5Gc9Ac
KDN
Reagent
peak
Neu5,7(8),9Ac3Gc
ReagentReagent
peak
22
PERMETHYLATIONPERMETHYLATION
 Population analysis by MALDI MS Population analysis by MALDI-MS
 Identification of glycan compositions and an initial
assessment of the types of structures presentassessment of the types of structures present
 Electrospray analysis
 A determination of glycan antennae present in the
sample through fragmentation of the glycans.
 Identification of unwanted epitopes eg GalαGalp p g
 GC-MS
 Identification of monosaccharide linkages in the
population
23
MALDI MS ANALYSIS OF N GLYCANSMALDI-MS ANALYSIS OF N-GLYCANS
Secretory glycoprotein
Antibody
24
FRAGMENTATION IN ELECTROSPRAY IONISATIONFRAGMENTATION IN ELECTROSPRAY IONISATION
O
OO O
CH2OR
O
CH2OR
+
OO O
OR OR OR OR
H
H NA
A-type oxonium ion cleavage
HexNAc
or
Sialic Acid
O
CH2OR
+
O
OR OR
25
OR OR
NANOSPRAY MS/MS ANALYSIS (Q-TOF)NANOSPRAY MS/MS ANALYSIS (Q-TOF)
Fetuin permethylated N-glycans
MS/MS 1791 ([M+2H]2+)
Consistent with the composition
NeuAc Hex HexNAc
NeuAc+ - methanol NeuAcHexHexNAc+ - methanol
344 2
MS/MS 1791 ([M+2H]2 ) NeuAc3Hex6HexNAc5
NeuAcHexHexNAc+
100
344.2
825.5
NeuAc+
%%
376.2
793.5 1792.0
200 400 600 800 1000 1200 1400 1600 1800
m/z0
26
200 400 600 800 1000 1200 1400 1600 1800
MS/MS OF THE SIGNAL AT M/Z 895 5MS/MS OF THE SIGNAL AT M/Z 895.5
298.2
CH2OMe
CH2OMeMeOCH2
CH
CHNMeAc
CHOMe
CHOMe
OHC
CC
MeOC
HH
H
C O
H
OMeOC
MeOCH
H
COOMe
AcNMeC
C
H
O
MeOCH
CHOMe
CH2OMe
OMeOC
H
H
H
C
H
C
OMe
AcNMeC
620.3
520.3
376 2/398 2376.2/398.2
NeuAcHexHexNAcitol + Na+
27
MS/MS OF THE SIGNAL AT M/Z 895 5MS/MS OF THE SIGNAL AT M/Z 895.5
298.2
298.2
CH2OMe
CH2OMeMeOCH2
CH
CHNMeAc
CHOMe
CHOMe
OHC
CC
MeOC
HH
H
C O
H
OMeOC
MeOCH
H
COOMe
AcNMeC
C
H
O
MeOCH
CHOMe
CH2OMe
OMeOC
H
H
H
C
H
C
OMe
AcNMeC
NeuAcHexHexNAcitol + Na+
28
MS/MS OF THE SIGNAL AT M/Z 1256.6
CH2OMe
CH
CHNMeAc
O
C O
H
CH2OMe
M OCH
MeOCH
MeOCH2
620.3
CH
CHOMe
CHOMe
CH
OHC
CC
MeOC
HH
H
H
OMeOC
MeOCH
H
H
H
COOMe
C
H
C
AcNMeC
C
H
O
CH2H
OMe
MeOCH
MeOCH2
881.5
659.3376.2/398.2
OC
MeOCH
H
H
H
COOMe
C
H
C
AcNMeC
C
H
O
284.2
H
OMe 506.3
376.2/398.2
NeuAcHexHexNAcitol + Na+
29
MS/MS OF THE SIGNAL AT M/Z 1256.6
CH2OMe
CH
CHNMeAc
O
C O
H
CH2OMe
M OCH
MeOCH
MeOCH2
CH
CHOMe
CHOMe
CH
OHC
CC
MeOC
HH
H
H
OMeOC
MeOCH
H
H
H
COOMe
C
H
C
AcNMeC
C
H
O
CH2H
OMe
MeOCH
MeOCH2
659.3
OC
MeOCH
H
H
H
COOMe
C
H
C
AcNMeC
C
H
O
659.3 H
OMe
659.3
NeuAcHexHexNAcitol + Na+
30
LINKAGE ANALYSIS
45
 GC/EI-MS analysis – Spectrum of 1,2-linked Mannose
LINKAGE ANALYSIS
OAc
OAc
CH3O
CH2OCH3
H
45
H OAc
CH2OCH3
117
161
306
129OAc
OCH3 OAc
D
H OCH3
H OCH3
161
205
190
234129
130
129
130
CHDOAc
H OAc 277
74
146
161 74
190
161
190
31
LINKAGE ANALYSIS
73
 GC/EI-MS analysis – spectrum of 1,3,6-linked Mannose
LINKAGE ANALYSIS
OA
CH2OAc
73
H OAc
CH2OAc
145
189
306
129
OAc
OAc
CH3O
H
D H OAc
H OCH3
189
261
190
234
118 129
OAc OCH3
CHDOAc
H OCH3
305
74
118
129
74
234
189
32
LINKAGE ANALYSIS
45
 GC/EI-MS analysis – spectrum of 1,4-linked N-Acetylglucosamine
LINKAGE ANALYSIS
OAc
OAc
AcO
CH2OCH3
H
45
H OAc
CH2OCH3
117
189
347
OAc
OCH3 NCH3Ac
D
OCH3H
H OAc
189
233
203
275117
CHDOAc
H NCH3Ac305
74
159117
74
159
233
33
LINKAGE ANALYSISLINKAGE ANALYSIS
100
16.752 117+118+129+159
3.33e6
RT
4-GlcNAc
%
6 G l
14.001
t-Gal
2-Man
3-Gal
6-Gal
2,4-Man
4,6-GlcNAc
10.000 11.000 12.000 13.000 14.000 15.000 16.000 17.000 18.000 19.000 20.000
rt0
13.171
13.471 14.941
t-Gal
3,6-Man
,
34
STEREOSPECIFICITY OF LINKAGE
3363.3
90
100
Voyager Spec #1=>SM3=>AdvBC(32,0.5,0.1)[BP = 2041.4, 4588]
681.5
Mixture of Gal1-3Gal1-4Gal1-3Gal (Mass 885Da)
and Gal1-4GlcNAc1-3Gal1-4Glc (Mass 926 Da)
Incubated with -Galactosidase
681.5
50
60
70
80
%Intensity
926.7
926.7
00
10
20
30
40
%
599.0 719.2 839.4 959.6 1079.8 1200.0
Mass (m/z)
00
2728 6100
Voyager Spec #1=>SM3=>AdvBC(32,0.5,0.1)[BP = 1836.2, 4445]
885.5722 4
Mixture of Gal1-3Gal1-4Gal1-3Gal (Mass 885 Da)
and Gal1-4GlcNAc1-3Gal1-4Glc (Mass 926 Da)885.5722 5 2728.6
60
70
80
90
100 722.4 and Gal1 4GlcNAc1 3Gal1 4Glc (Mass 926 Da)
Incubated with -Galactosidase
885.5722.5
20
30
40
50
%Intensity
35
599.0 719.2 839.4 959.6 1079.8 1200.0
Mass (m/z)
00
10
2 AB STACKED CHROMATOGRAMS2-AB STACKED CHROMATOGRAMS
Five separate Mab N glycan preparationsFive separate Mab N-glycan preparations
G0F G1F G2F
Run 1 0.59 0.32 0.09
Run 2 0.58 0.32 0.09
Run 3 0.59 0.32 0.09
Run 4 0.58 0.33 0.09
Run 5 0 58 0 32 0 09Run 5 0.58 0.32 0.09
Average 0.584 0.322 0.09
SD 0.0055 0.0045 0.00
%CV 0.94 1.40 0.00
36
2 AB STACKED CHROMATOGRAMS2-AB STACKED CHROMATOGRAMS
Diff i t f M b tiDiffering amounts of Mab preparations
100μg
10μg
50μg
37
TAKE HOME MESSAGESTAKE HOME MESSAGES
 Mass spectrometric analysis provides detailed structural information on
composition, antennal structures and linkage.
 Chromatography provides a unique glycan profile due to the precise
structure and associated interactions of the glycans with the column
t i Thi fil b d f i t hi h thmatrix. This profile can be used as a reference against which other
batches can be compared. Useful for characterisation, stability, forced
degradation studies.
 The use of LC/ES-MS of proteolytic digests allows sites of glycosylation
to be isolated and identified. These sites can then be analysed using the
b t h i t d t i th t f th l t h itabove techniques to determine the nature of the glycans at each site.
38
CARBOHYDRATES MAKE IT ON TV!CARBOHYDRATES MAKE IT ON TV!
39
THANK YOU FOR YOUR ATTENTIONTHANK YOU FOR YOUR ATTENTION
Life Science Services Dr Andrew J Reason
Group Manager SGS M-Scan Europe
SGS M Scan Ltd Phone: +44 (0) 118 989 6940
Life Science Services Dr Richard Easton
Team Leader, Carbohydrate Analysis
SGS M S Ltd Ph 44 (0) 118 912 1190
+ 41 22 739 9548
SGS M-Scan Ltd Phone: +44 (0) 118 989 6940
2-3 Millars Business Centre, Fax: +44 (0) 118 989 6941
Fishponds Close, E-mail : andrew.reason@sgs.com
Wokingham
Berkshire, RG41 2TZ, UK Web : www.sgs.com/biopharma
SGS M-Scan Ltd Phone: +44 (0) 118 912 1190
2-3 Millars Business Centre, Fax: +44 (0) 118 912 1191
Fishponds Close, E-mail : uk.biopharma@sgs.com
Wokingham E-mail : richard.easton@sgs.com
Berkshire, RG41 2TZ, UK Web : www.sgs.com/biopharma
+ 1 866 SGS 5003
+ 65 637 90 111
+ 33 1 41 24 87 87
+ 1 877 677 2667
40
1 877 677 2667
QUESTIONS ?QUESTIONS ?
41

More Related Content

What's hot

Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...
Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...
Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...
FirstSource Laboratory Solutions
 
Scaffold hopping in drug development ppt
Scaffold hopping in drug development  pptScaffold hopping in drug development  ppt
Scaffold hopping in drug development ppt
AkliluSamuel3
 
High throughput screening
High throughput screening High throughput screening
High throughput screening
RewariBhavya
 
Corrositex®/OECD 435 Demonstration - Dermal Corrosion Testing
Corrositex®/OECD 435 Demonstration - Dermal Corrosion TestingCorrositex®/OECD 435 Demonstration - Dermal Corrosion Testing
Corrositex®/OECD 435 Demonstration - Dermal Corrosion Testing
Dell Tech
 
Stability testing of biotechnological/ biological products (Q5C )
Stability testing of biotechnological/ biological products (Q5C )Stability testing of biotechnological/ biological products (Q5C )
Stability testing of biotechnological/ biological products (Q5C )
UshaKhanal3
 
Principles & Applications of cell viability assays (MTT Assays)
Principles & Applications of cell viability assays (MTT Assays)Principles & Applications of cell viability assays (MTT Assays)
Principles & Applications of cell viability assays (MTT Assays)
VidyaNani
 
3. Cellular cytotoxicity
3. Cellular cytotoxicity3. Cellular cytotoxicity
3. Cellular cytotoxicity
Shailendra shera
 
1. An Overview of Drug Discovery Process.pdf
1. An Overview of Drug Discovery Process.pdf1. An Overview of Drug Discovery Process.pdf
1. An Overview of Drug Discovery Process.pdf
Yogeshwary Bhongade
 
Human liver microsomes & rat liver microsomes
Human liver microsomes & rat liver microsomesHuman liver microsomes & rat liver microsomes
Human liver microsomes & rat liver microsomes
gaurav sharma
 
drug discovery- history, evolution and stages
drug discovery- history, evolution and stagesdrug discovery- history, evolution and stages
drug discovery- history, evolution and stages
aiswarya thomas
 
In vitro testing of rug toxicity
In vitro testing of rug toxicityIn vitro testing of rug toxicity
In vitro testing of rug toxicity
Dr Vijayata choudhary
 
HPLC-COLUMNS
HPLC-COLUMNS HPLC-COLUMNS
In silico drug desigining
In silico drug desiginingIn silico drug desigining
In silico drug desigining
Devesh Shukla
 
Biosimilar Drugs
Biosimilar DrugsBiosimilar Drugs
Biosimilar Drugs
UshaKhanal3
 
Cell culture technique
Cell culture techniqueCell culture technique
Cell culture technique
irtizaashaq
 
Immunoassays
ImmunoassaysImmunoassays
Immunoassays
Dhwani Khandhar
 
REGULATORY SIGNIFICANCE AND SALIENT FEATURES OF GOOD LABORATORY PRACTICE (GLP...
REGULATORY SIGNIFICANCE AND SALIENT FEATURES OFGOOD LABORATORY PRACTICE (GLP...REGULATORY SIGNIFICANCE AND SALIENT FEATURES OFGOOD LABORATORY PRACTICE (GLP...
REGULATORY SIGNIFICANCE AND SALIENT FEATURES OF GOOD LABORATORY PRACTICE (GLP...
Dr.Dhanya Nair
 
Cell based Assays
Cell based AssaysCell based Assays
Cell based Assays
Jesús C. Morales
 
Toxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptxToxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptx
ashharnomani
 
USFDA guidelines for bioanalytical method validation
USFDA guidelines for bioanalytical method validationUSFDA guidelines for bioanalytical method validation
USFDA guidelines for bioanalytical method validation
bhatiaji123
 

What's hot (20)

Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...
Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...
Nanoliter Scale Immunoassays for Time Critical Workflows - Gyros Protein Tech...
 
Scaffold hopping in drug development ppt
Scaffold hopping in drug development  pptScaffold hopping in drug development  ppt
Scaffold hopping in drug development ppt
 
High throughput screening
High throughput screening High throughput screening
High throughput screening
 
Corrositex®/OECD 435 Demonstration - Dermal Corrosion Testing
Corrositex®/OECD 435 Demonstration - Dermal Corrosion TestingCorrositex®/OECD 435 Demonstration - Dermal Corrosion Testing
Corrositex®/OECD 435 Demonstration - Dermal Corrosion Testing
 
Stability testing of biotechnological/ biological products (Q5C )
Stability testing of biotechnological/ biological products (Q5C )Stability testing of biotechnological/ biological products (Q5C )
Stability testing of biotechnological/ biological products (Q5C )
 
Principles & Applications of cell viability assays (MTT Assays)
Principles & Applications of cell viability assays (MTT Assays)Principles & Applications of cell viability assays (MTT Assays)
Principles & Applications of cell viability assays (MTT Assays)
 
3. Cellular cytotoxicity
3. Cellular cytotoxicity3. Cellular cytotoxicity
3. Cellular cytotoxicity
 
1. An Overview of Drug Discovery Process.pdf
1. An Overview of Drug Discovery Process.pdf1. An Overview of Drug Discovery Process.pdf
1. An Overview of Drug Discovery Process.pdf
 
Human liver microsomes & rat liver microsomes
Human liver microsomes & rat liver microsomesHuman liver microsomes & rat liver microsomes
Human liver microsomes & rat liver microsomes
 
drug discovery- history, evolution and stages
drug discovery- history, evolution and stagesdrug discovery- history, evolution and stages
drug discovery- history, evolution and stages
 
In vitro testing of rug toxicity
In vitro testing of rug toxicityIn vitro testing of rug toxicity
In vitro testing of rug toxicity
 
HPLC-COLUMNS
HPLC-COLUMNS HPLC-COLUMNS
HPLC-COLUMNS
 
In silico drug desigining
In silico drug desiginingIn silico drug desigining
In silico drug desigining
 
Biosimilar Drugs
Biosimilar DrugsBiosimilar Drugs
Biosimilar Drugs
 
Cell culture technique
Cell culture techniqueCell culture technique
Cell culture technique
 
Immunoassays
ImmunoassaysImmunoassays
Immunoassays
 
REGULATORY SIGNIFICANCE AND SALIENT FEATURES OF GOOD LABORATORY PRACTICE (GLP...
REGULATORY SIGNIFICANCE AND SALIENT FEATURES OFGOOD LABORATORY PRACTICE (GLP...REGULATORY SIGNIFICANCE AND SALIENT FEATURES OFGOOD LABORATORY PRACTICE (GLP...
REGULATORY SIGNIFICANCE AND SALIENT FEATURES OF GOOD LABORATORY PRACTICE (GLP...
 
Cell based Assays
Cell based AssaysCell based Assays
Cell based Assays
 
Toxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptxToxicokinetic evaluation in preclinical studies.pptx
Toxicokinetic evaluation in preclinical studies.pptx
 
USFDA guidelines for bioanalytical method validation
USFDA guidelines for bioanalytical method validationUSFDA guidelines for bioanalytical method validation
USFDA guidelines for bioanalytical method validation
 

Viewers also liked

BioTech Journey through the Phases of Commercializing a Product
BioTech Journey through the Phases of Commercializing a ProductBioTech Journey through the Phases of Commercializing a Product
BioTech Journey through the Phases of Commercializing a Product
CBG Benefits
 
Mass spectrometry
Mass spectrometryMass spectrometry
Mass spectrometry
Roland Stenutz
 
PEGS the essential protein and antibody engineering summit
PEGS the essential protein and antibody engineering summit PEGS the essential protein and antibody engineering summit
PEGS the essential protein and antibody engineering summit
Nicole Proulx
 
PepTalk: The Protein Science Week 2016
PepTalk: The Protein Science Week 2016PepTalk: The Protein Science Week 2016
PepTalk: The Protein Science Week 2016
Nicole Proulx
 
Biosimilars
Biosimilars Biosimilars
Biosimilars
Dr. Maheshi Chhaya
 
9 Karin Heidenreich - Novartis
9 Karin Heidenreich -  Novartis9 Karin Heidenreich -  Novartis
Infliximab life of a biotherapeutic comments v5
Infliximab life of a biotherapeutic comments v5Infliximab life of a biotherapeutic comments v5
Infliximab life of a biotherapeutic comments v5
Larry Hines
 
Biosimilars
BiosimilarsBiosimilars
Cmc biologics pathway_draft8
Cmc biologics pathway_draft8Cmc biologics pathway_draft8
Cmc biologics pathway_draft8
enarke
 
Advances in LC/MS methodologies for the characterisation of complex glycoprot...
Advances in LC/MS methodologies for the characterisation of complex glycoprot...Advances in LC/MS methodologies for the characterisation of complex glycoprot...
Advances in LC/MS methodologies for the characterisation of complex glycoprot...
Quality Assistance s.a.
 

Viewers also liked (11)

BioTech Journey through the Phases of Commercializing a Product
BioTech Journey through the Phases of Commercializing a ProductBioTech Journey through the Phases of Commercializing a Product
BioTech Journey through the Phases of Commercializing a Product
 
Mass spectrometry
Mass spectrometryMass spectrometry
Mass spectrometry
 
PEGS the essential protein and antibody engineering summit
PEGS the essential protein and antibody engineering summit PEGS the essential protein and antibody engineering summit
PEGS the essential protein and antibody engineering summit
 
PepTalk: The Protein Science Week 2016
PepTalk: The Protein Science Week 2016PepTalk: The Protein Science Week 2016
PepTalk: The Protein Science Week 2016
 
Biosimilars
Biosimilars Biosimilars
Biosimilars
 
Ifpma - Current development reg strategies for biotherapeutic products - Jane...
Ifpma - Current development reg strategies for biotherapeutic products - Jane...Ifpma - Current development reg strategies for biotherapeutic products - Jane...
Ifpma - Current development reg strategies for biotherapeutic products - Jane...
 
9 Karin Heidenreich - Novartis
9 Karin Heidenreich -  Novartis9 Karin Heidenreich -  Novartis
9 Karin Heidenreich - Novartis
 
Infliximab life of a biotherapeutic comments v5
Infliximab life of a biotherapeutic comments v5Infliximab life of a biotherapeutic comments v5
Infliximab life of a biotherapeutic comments v5
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
Cmc biologics pathway_draft8
Cmc biologics pathway_draft8Cmc biologics pathway_draft8
Cmc biologics pathway_draft8
 
Advances in LC/MS methodologies for the characterisation of complex glycoprot...
Advances in LC/MS methodologies for the characterisation of complex glycoprot...Advances in LC/MS methodologies for the characterisation of complex glycoprot...
Advances in LC/MS methodologies for the characterisation of complex glycoprot...
 

Similar to Glycan Structural Analysis Throughout Biotherapeutic Development

Uploaded file 130063322505815833
Uploaded file 130063322505815833Uploaded file 130063322505815833
Uploaded file 130063322505815833준호 유
 
Uploaded file 130063321946083603
Uploaded file 130063321946083603Uploaded file 130063321946083603
Uploaded file 130063321946083603준호 유
 
Fall 2015 Sitag Poster _120516 (1)-2
Fall 2015 Sitag Poster _120516 (1)-2Fall 2015 Sitag Poster _120516 (1)-2
Fall 2015 Sitag Poster _120516 (1)-2Adam Hildebrandt
 
INLIGHT App Note 37
INLIGHT App Note 37INLIGHT App Note 37
INLIGHT App Note 37Amber Cook
 
Conservation of codon optimality
Conservation of codon optimalityConservation of codon optimality
Conservation of codon optimality
Alistair Martin
 
Paloma Pérez-Enfermedades raras de la piel
Paloma Pérez-Enfermedades raras de la pielPaloma Pérez-Enfermedades raras de la piel
Paloma Pérez-Enfermedades raras de la piel
Fundación Ramón Areces
 
Bacterial Periplasmic Binding Proteins as Biosensors in Liposomes
Bacterial Periplasmic Binding Proteins as Biosensors in LiposomesBacterial Periplasmic Binding Proteins as Biosensors in Liposomes
Bacterial Periplasmic Binding Proteins as Biosensors in Liposomes
Heather Jordan
 
A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...
A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...
A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...
星云 王
 
Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...
Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...
Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...
ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY
 
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
SGS
 
Molecular Biology
Molecular Biology Molecular Biology
Molecular Biology
Zagazig University
 
Cellular Neuroscience Products
Cellular Neuroscience ProductsCellular Neuroscience Products
Cellular Neuroscience Products
cailynnjohnson
 
Molecular docking MAPK.pptx
Molecular docking MAPK.pptxMolecular docking MAPK.pptx
Molecular docking MAPK.pptx
Samson Raj Y
 
Francisco Zafra Centro de Biologia Molecular Severo Ochoa. CSIC-UAM.
Francisco Zafra  Centro de Biologia Molecular Severo Ochoa. CSIC-UAM. Francisco Zafra  Centro de Biologia Molecular Severo Ochoa. CSIC-UAM.
Francisco Zafra Centro de Biologia Molecular Severo Ochoa. CSIC-UAM.
Fundación Ramón Areces
 
GM Food Allergy Biomarkers
GM Food Allergy BiomarkersGM Food Allergy Biomarkers
GM Food Allergy BiomarkersMainul Husain
 
Plugin glycosylation literature survey ricky connolly 091211-1
Plugin glycosylation literature survey ricky connolly 091211-1Plugin glycosylation literature survey ricky connolly 091211-1
Plugin glycosylation literature survey ricky connolly 091211-1Patrick Connolly
 
Glycosylation literature survey ricky connolly 091211
Glycosylation literature survey ricky connolly 091211Glycosylation literature survey ricky connolly 091211
Glycosylation literature survey ricky connolly 091211ricky_connolly
 

Similar to Glycan Structural Analysis Throughout Biotherapeutic Development (20)

Uploaded file 130063322505815833
Uploaded file 130063322505815833Uploaded file 130063322505815833
Uploaded file 130063322505815833
 
Uploaded file 130063321946083603
Uploaded file 130063321946083603Uploaded file 130063321946083603
Uploaded file 130063321946083603
 
Fall 2015 Sitag Poster _120516 (1)-2
Fall 2015 Sitag Poster _120516 (1)-2Fall 2015 Sitag Poster _120516 (1)-2
Fall 2015 Sitag Poster _120516 (1)-2
 
Symposium 2012
Symposium 2012Symposium 2012
Symposium 2012
 
Ryzakovas_BS984_Poster
Ryzakovas_BS984_PosterRyzakovas_BS984_Poster
Ryzakovas_BS984_Poster
 
INLIGHT App Note 37
INLIGHT App Note 37INLIGHT App Note 37
INLIGHT App Note 37
 
Conservation of codon optimality
Conservation of codon optimalityConservation of codon optimality
Conservation of codon optimality
 
Paloma Pérez-Enfermedades raras de la piel
Paloma Pérez-Enfermedades raras de la pielPaloma Pérez-Enfermedades raras de la piel
Paloma Pérez-Enfermedades raras de la piel
 
Bacterial Periplasmic Binding Proteins as Biosensors in Liposomes
Bacterial Periplasmic Binding Proteins as Biosensors in LiposomesBacterial Periplasmic Binding Proteins as Biosensors in Liposomes
Bacterial Periplasmic Binding Proteins as Biosensors in Liposomes
 
A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...
A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...
A reading report for <A Secreted Slit2 Fragment Regulates Adipose Tissue Ther...
 
Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...
Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...
Effects of Gallic Acid on Ischemia-Reperfusion Induced Testicular Injury in a...
 
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
 
Molecular Biology
Molecular Biology Molecular Biology
Molecular Biology
 
ASCB poster
ASCB posterASCB poster
ASCB poster
 
Cellular Neuroscience Products
Cellular Neuroscience ProductsCellular Neuroscience Products
Cellular Neuroscience Products
 
Molecular docking MAPK.pptx
Molecular docking MAPK.pptxMolecular docking MAPK.pptx
Molecular docking MAPK.pptx
 
Francisco Zafra Centro de Biologia Molecular Severo Ochoa. CSIC-UAM.
Francisco Zafra  Centro de Biologia Molecular Severo Ochoa. CSIC-UAM. Francisco Zafra  Centro de Biologia Molecular Severo Ochoa. CSIC-UAM.
Francisco Zafra Centro de Biologia Molecular Severo Ochoa. CSIC-UAM.
 
GM Food Allergy Biomarkers
GM Food Allergy BiomarkersGM Food Allergy Biomarkers
GM Food Allergy Biomarkers
 
Plugin glycosylation literature survey ricky connolly 091211-1
Plugin glycosylation literature survey ricky connolly 091211-1Plugin glycosylation literature survey ricky connolly 091211-1
Plugin glycosylation literature survey ricky connolly 091211-1
 
Glycosylation literature survey ricky connolly 091211
Glycosylation literature survey ricky connolly 091211Glycosylation literature survey ricky connolly 091211
Glycosylation literature survey ricky connolly 091211
 

More from SGS

SGS First Quarter 2024 Sales Update Press Release EN.pdf
SGS First Quarter 2024 Sales Update Press Release EN.pdfSGS First Quarter 2024 Sales Update Press Release EN.pdf
SGS First Quarter 2024 Sales Update Press Release EN.pdf
SGS
 
SGS First Quarter 2024 Sales Update Presentation EN.pdf
SGS First Quarter 2024 Sales Update Presentation EN.pdfSGS First Quarter 2024 Sales Update Presentation EN.pdf
SGS First Quarter 2024 Sales Update Presentation EN.pdf
SGS
 
SGS 2023 Full Year Results Earnings Release EN.pdf
SGS 2023 Full Year Results Earnings Release EN.pdfSGS 2023 Full Year Results Earnings Release EN.pdf
SGS 2023 Full Year Results Earnings Release EN.pdf
SGS
 
SGS 2023 Results and Strategic Update.pdf
SGS 2023 Results and Strategic Update.pdfSGS 2023 Results and Strategic Update.pdf
SGS 2023 Results and Strategic Update.pdf
SGS
 
SGS 2023 Half Year Results Presentation
SGS 2023 Half Year Results PresentationSGS 2023 Half Year Results Presentation
SGS 2023 Half Year Results Presentation
SGS
 
SGS 2023 Half Year Results Report
SGS 2023 Half Year Results ReportSGS 2023 Half Year Results Report
SGS 2023 Half Year Results Report
SGS
 
SGS 2022 Full Year Results Presentation
SGS 2022 Full Year Results PresentationSGS 2022 Full Year Results Presentation
SGS 2022 Full Year Results Presentation
SGS
 
SGS 2022 Full Year Results Alternative Performance Measures Report
SGS 2022 Full Year Results Alternative Performance Measures ReportSGS 2022 Full Year Results Alternative Performance Measures Report
SGS 2022 Full Year Results Alternative Performance Measures Report
SGS
 
SGS 2022 Full Year Results Report
SGS 2022 Full Year Results ReportSGS 2022 Full Year Results Report
SGS 2022 Full Year Results Report
SGS
 
SGS 2022 Half Year Results Report
SGS 2022 Half Year Results ReportSGS 2022 Half Year Results Report
SGS 2022 Half Year Results Report
SGS
 
SGS 2022 Half Year Results Alternative Performance Measures Report
SGS 2022 Half Year Results Alternative Performance Measures ReportSGS 2022 Half Year Results Alternative Performance Measures Report
SGS 2022 Half Year Results Alternative Performance Measures Report
SGS
 
SGS 2022 Half Year Results Presentation
SGS 2022 Half Year Results PresentationSGS 2022 Half Year Results Presentation
SGS 2022 Half Year Results Presentation
SGS
 
SGS 2021 Corporate Sustainability Report
SGS 2021 Corporate Sustainability ReportSGS 2021 Corporate Sustainability Report
SGS 2021 Corporate Sustainability Report
SGS
 
SGS 2021 Integrated Annual Report
SGS 2021 Integrated Annual ReportSGS 2021 Integrated Annual Report
SGS 2021 Integrated Annual Report
SGS
 
SGS 2021 Full Year Results Report
SGS 2021 Full Year Results ReportSGS 2021 Full Year Results Report
SGS 2021 Full Year Results Report
SGS
 
SGS 2021 Full Year Results Alternative Performance Measures
SGS 2021 Full Year Results Alternative Performance MeasuresSGS 2021 Full Year Results Alternative Performance Measures
SGS 2021 Full Year Results Alternative Performance Measures
SGS
 
SGS Intron Bulletin
SGS Intron BulletinSGS Intron Bulletin
SGS Intron Bulletin
SGS
 
Danone Fruit Supply Chain Mapping via Transparency-One Platform
Danone Fruit Supply Chain Mapping via Transparency-One PlatformDanone Fruit Supply Chain Mapping via Transparency-One Platform
Danone Fruit Supply Chain Mapping via Transparency-One Platform
SGS
 
SGS 2021 Half Year Results Alternative Performance Measures Report
SGS 2021 Half Year Results Alternative Performance Measures ReportSGS 2021 Half Year Results Alternative Performance Measures Report
SGS 2021 Half Year Results Alternative Performance Measures Report
SGS
 
SGS 2021 Half Year Results Presentation
SGS 2021 Half Year Results PresentationSGS 2021 Half Year Results Presentation
SGS 2021 Half Year Results Presentation
SGS
 

More from SGS (20)

SGS First Quarter 2024 Sales Update Press Release EN.pdf
SGS First Quarter 2024 Sales Update Press Release EN.pdfSGS First Quarter 2024 Sales Update Press Release EN.pdf
SGS First Quarter 2024 Sales Update Press Release EN.pdf
 
SGS First Quarter 2024 Sales Update Presentation EN.pdf
SGS First Quarter 2024 Sales Update Presentation EN.pdfSGS First Quarter 2024 Sales Update Presentation EN.pdf
SGS First Quarter 2024 Sales Update Presentation EN.pdf
 
SGS 2023 Full Year Results Earnings Release EN.pdf
SGS 2023 Full Year Results Earnings Release EN.pdfSGS 2023 Full Year Results Earnings Release EN.pdf
SGS 2023 Full Year Results Earnings Release EN.pdf
 
SGS 2023 Results and Strategic Update.pdf
SGS 2023 Results and Strategic Update.pdfSGS 2023 Results and Strategic Update.pdf
SGS 2023 Results and Strategic Update.pdf
 
SGS 2023 Half Year Results Presentation
SGS 2023 Half Year Results PresentationSGS 2023 Half Year Results Presentation
SGS 2023 Half Year Results Presentation
 
SGS 2023 Half Year Results Report
SGS 2023 Half Year Results ReportSGS 2023 Half Year Results Report
SGS 2023 Half Year Results Report
 
SGS 2022 Full Year Results Presentation
SGS 2022 Full Year Results PresentationSGS 2022 Full Year Results Presentation
SGS 2022 Full Year Results Presentation
 
SGS 2022 Full Year Results Alternative Performance Measures Report
SGS 2022 Full Year Results Alternative Performance Measures ReportSGS 2022 Full Year Results Alternative Performance Measures Report
SGS 2022 Full Year Results Alternative Performance Measures Report
 
SGS 2022 Full Year Results Report
SGS 2022 Full Year Results ReportSGS 2022 Full Year Results Report
SGS 2022 Full Year Results Report
 
SGS 2022 Half Year Results Report
SGS 2022 Half Year Results ReportSGS 2022 Half Year Results Report
SGS 2022 Half Year Results Report
 
SGS 2022 Half Year Results Alternative Performance Measures Report
SGS 2022 Half Year Results Alternative Performance Measures ReportSGS 2022 Half Year Results Alternative Performance Measures Report
SGS 2022 Half Year Results Alternative Performance Measures Report
 
SGS 2022 Half Year Results Presentation
SGS 2022 Half Year Results PresentationSGS 2022 Half Year Results Presentation
SGS 2022 Half Year Results Presentation
 
SGS 2021 Corporate Sustainability Report
SGS 2021 Corporate Sustainability ReportSGS 2021 Corporate Sustainability Report
SGS 2021 Corporate Sustainability Report
 
SGS 2021 Integrated Annual Report
SGS 2021 Integrated Annual ReportSGS 2021 Integrated Annual Report
SGS 2021 Integrated Annual Report
 
SGS 2021 Full Year Results Report
SGS 2021 Full Year Results ReportSGS 2021 Full Year Results Report
SGS 2021 Full Year Results Report
 
SGS 2021 Full Year Results Alternative Performance Measures
SGS 2021 Full Year Results Alternative Performance MeasuresSGS 2021 Full Year Results Alternative Performance Measures
SGS 2021 Full Year Results Alternative Performance Measures
 
SGS Intron Bulletin
SGS Intron BulletinSGS Intron Bulletin
SGS Intron Bulletin
 
Danone Fruit Supply Chain Mapping via Transparency-One Platform
Danone Fruit Supply Chain Mapping via Transparency-One PlatformDanone Fruit Supply Chain Mapping via Transparency-One Platform
Danone Fruit Supply Chain Mapping via Transparency-One Platform
 
SGS 2021 Half Year Results Alternative Performance Measures Report
SGS 2021 Half Year Results Alternative Performance Measures ReportSGS 2021 Half Year Results Alternative Performance Measures Report
SGS 2021 Half Year Results Alternative Performance Measures Report
 
SGS 2021 Half Year Results Presentation
SGS 2021 Half Year Results PresentationSGS 2021 Half Year Results Presentation
SGS 2021 Half Year Results Presentation
 

Recently uploaded

HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
priyabhojwani1200
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
AnushriSrivastav
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 
Essential Metrics for Palliative Care Management
Essential Metrics for Palliative Care ManagementEssential Metrics for Palliative Care Management
Essential Metrics for Palliative Care Management
Care Coordinations
 
10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience
ranishasharma67
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
ILC- UK
 
Introduction to Forensic Pathology course
Introduction to Forensic Pathology courseIntroduction to Forensic Pathology course
Introduction to Forensic Pathology course
fprxsqvnz5
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
o6ov5dqmf
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
PGIMS Rohtak
 
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
ranishasharma67
 
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptxGLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
priyabhojwani1200
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
Sachin Sharma
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
Aboud Health Group
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
NEHA GUPTA
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
The Importance of Community Nursing Care.pdf
The Importance of Community Nursing Care.pdfThe Importance of Community Nursing Care.pdf
The Importance of Community Nursing Care.pdf
AD Healthcare
 
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
ranishasharma67
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
Kumar Satyam
 

Recently uploaded (20)

HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 
Essential Metrics for Palliative Care Management
Essential Metrics for Palliative Care ManagementEssential Metrics for Palliative Care Management
Essential Metrics for Palliative Care Management
 
10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
 
Introduction to Forensic Pathology course
Introduction to Forensic Pathology courseIntroduction to Forensic Pathology course
Introduction to Forensic Pathology course
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
 
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
GURGAON Call Girls ❤8901183002❤ #ℂALL# #gIRLS# In GURGAON ₹,2500 Cash Payment...
 
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptxGLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
The Importance of Community Nursing Care.pdf
The Importance of Community Nursing Care.pdfThe Importance of Community Nursing Care.pdf
The Importance of Community Nursing Care.pdf
 
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
 

Glycan Structural Analysis Throughout Biotherapeutic Development

  • 1. GLYCAN STRUCTURAL ANALYSIS THROUGHOUT BIOTHERAPEUTIC DEVELOPMENT Dr Richard Easton Team Leader Carbohydrate AnalysisTeam Leader, Carbohydrate Analysis SGS Life Science Services Wokingham, UK
  • 2.  What is glycosylation? What is glycosylation?  What aspects of glycosylation are key? What aspects of glycosylation are key? H th b i ti t d? How can these be investigated? 2
  • 3. N GLYCOSYLATIONN-GLYCOSYLATION  Attached to Asn in the consensus Attached to Asn in the consensus sequence …Asn-X-Ser/Thr…where X is any AA except Pro  Initiated in ER by en bloc transfer of a pre- formed lipid-anchored conserved glycan  Mature glycans formed by trimming (in ER and Golgi) and elongation (Golgi)  Found on mammalian, insect, fungal, bacterial and plant cell proteins 3
  • 4. O GLYCOSYLATIONO-GLYCOSYLATION  Occurs on Ser and ThrOccurs on Ser and Thr  No consensus sequence but some “rules” eg nearby proline, tandem repeats of Ser/Thr  Initiated in Golgi by addition of a single sugar - usually GalNAc in mammals  Additi l dd d ti ll t f th Additional sugars are added sequentially to form the core sequence and then the antennae  Cores 1 & 2 are very common in many glycoproteinsy y g y p  Other monosaccharides may act as linkers depending on the protein structure eg O-linked Fucose in EGF domains  Cores 1 & 2 are very common in many glycoproteins  Found on mammalian, insect, fungal, bacterial and plant cells 4
  • 6. EUKARYOTIC N GLYCAN BIOSYNTHESISEUKARYOTIC N-GLYCAN BIOSYNTHESIS 6
  • 7. IN YEAST HIGH MANNOSE GLYCANS ARE MADE LARGER BY POLYMANNOSYLATIONLARGER BY POLYMANNOSYLATION 7
  • 8. PLANTS AND INVERTEBRATES DECORATE THE N-GLYCAN CORE IN MORE DIVERSE WAYS THAN MAMMALS 8
  • 9. N-GLYCOSYLATION IN FISH AND BIRDSN-GLYCOSYLATION IN FISH AND BIRDS some fish glycans are the most decorated of all known glycans 9 decorated of all known glycans
  • 10. SELECTED MAMMALIAN N GLYCAN STRUCTURESSELECTED MAMMALIAN N-GLYCAN STRUCTURES (i) (iii) (ii) Erythropoietin Glycodelin S Gl d li A (iv) (v) +/- (vi) Glycodelin A +/- Tamm-Horsfall glycoprotein M kid Neutrophil 10 Mouse kidney
  • 11. O LINKED OLIGOSACCHARIDES CORES 1 AND 2O-LINKED OLIGOSACCHARIDES CORES 1 AND 2 11
  • 12. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 12
  • 13. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 13
  • 14. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 14
  • 15. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 15
  • 16. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 16
  • 17. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 17
  • 18. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 18
  • 19. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 19
  • 20. ANALYSIS OF GLYCOPROTEINSANALYSIS OF GLYCOPROTEINS 20
  • 21. MONOSACCHARIDE ANALYSIS – BOVINE FETUINO OS CC S S O U  Is my molecule glycosylated? • Is the glycosylation N linked and if so what type (complex high mannose)?M-Scan Ltd. Sample: Fetuin standard Job: 12849 Sample No:Acquired on: 29-Sep-2000 at 13:37:38 by: 100 % FETST299 Scan EI+ 298 6.30e4 21.83 N-Acetyl neuraminic acid • Is the glycosylation N-linked and if so what type (complex, high mannose)? • Is there evidence of O-glycosylation?  Is there evidence of carbohydrate contamination coming through the process? • High levels of glucose may indicate breakdown of, for example, gel filtration beads 100 0 % FETST299 Scan EI+ 173 1.56e5 16.98 N-Acetyl g g y , p , g 100 0 % 16.38 21.83 17.13 FETST299 Scan EI+ 20411.32 Galactose N-Acetyl galactosamine y glucosamine 0 100 % 3.69e512.08 12.65 13.12 13.48 16.98 21.83 FETST299 Scan EI+ Mannose Galactose Glucose 100 % FETST299 Scan EI+ TIC 3.99e6 10.28 7.72 7.00 21.83 11.32 12.08 11.47 16.98 13.12 12.65 13.50 Arabitol (IS) 21 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 Time0 7.72
  • 22. DMB SIALIC ACID ANALYSISDMB SIALIC ACID ANALYSIS Neu5Ac Neu5Gc Sialic acid reference panel Neu5,9Ac2 Neu5,7Ac2 Neu5Gc9Ac KDN Reagent peak Neu5,7(8),9Ac3Gc ReagentReagent peak 22
  • 23. PERMETHYLATIONPERMETHYLATION  Population analysis by MALDI MS Population analysis by MALDI-MS  Identification of glycan compositions and an initial assessment of the types of structures presentassessment of the types of structures present  Electrospray analysis  A determination of glycan antennae present in the sample through fragmentation of the glycans.  Identification of unwanted epitopes eg GalαGalp p g  GC-MS  Identification of monosaccharide linkages in the population 23
  • 24. MALDI MS ANALYSIS OF N GLYCANSMALDI-MS ANALYSIS OF N-GLYCANS Secretory glycoprotein Antibody 24
  • 25. FRAGMENTATION IN ELECTROSPRAY IONISATIONFRAGMENTATION IN ELECTROSPRAY IONISATION O OO O CH2OR O CH2OR + OO O OR OR OR OR H H NA A-type oxonium ion cleavage HexNAc or Sialic Acid O CH2OR + O OR OR 25 OR OR
  • 26. NANOSPRAY MS/MS ANALYSIS (Q-TOF)NANOSPRAY MS/MS ANALYSIS (Q-TOF) Fetuin permethylated N-glycans MS/MS 1791 ([M+2H]2+) Consistent with the composition NeuAc Hex HexNAc NeuAc+ - methanol NeuAcHexHexNAc+ - methanol 344 2 MS/MS 1791 ([M+2H]2 ) NeuAc3Hex6HexNAc5 NeuAcHexHexNAc+ 100 344.2 825.5 NeuAc+ %% 376.2 793.5 1792.0 200 400 600 800 1000 1200 1400 1600 1800 m/z0 26 200 400 600 800 1000 1200 1400 1600 1800
  • 27. MS/MS OF THE SIGNAL AT M/Z 895 5MS/MS OF THE SIGNAL AT M/Z 895.5 298.2 CH2OMe CH2OMeMeOCH2 CH CHNMeAc CHOMe CHOMe OHC CC MeOC HH H C O H OMeOC MeOCH H COOMe AcNMeC C H O MeOCH CHOMe CH2OMe OMeOC H H H C H C OMe AcNMeC 620.3 520.3 376 2/398 2376.2/398.2 NeuAcHexHexNAcitol + Na+ 27
  • 28. MS/MS OF THE SIGNAL AT M/Z 895 5MS/MS OF THE SIGNAL AT M/Z 895.5 298.2 298.2 CH2OMe CH2OMeMeOCH2 CH CHNMeAc CHOMe CHOMe OHC CC MeOC HH H C O H OMeOC MeOCH H COOMe AcNMeC C H O MeOCH CHOMe CH2OMe OMeOC H H H C H C OMe AcNMeC NeuAcHexHexNAcitol + Na+ 28
  • 29. MS/MS OF THE SIGNAL AT M/Z 1256.6 CH2OMe CH CHNMeAc O C O H CH2OMe M OCH MeOCH MeOCH2 620.3 CH CHOMe CHOMe CH OHC CC MeOC HH H H OMeOC MeOCH H H H COOMe C H C AcNMeC C H O CH2H OMe MeOCH MeOCH2 881.5 659.3376.2/398.2 OC MeOCH H H H COOMe C H C AcNMeC C H O 284.2 H OMe 506.3 376.2/398.2 NeuAcHexHexNAcitol + Na+ 29
  • 30. MS/MS OF THE SIGNAL AT M/Z 1256.6 CH2OMe CH CHNMeAc O C O H CH2OMe M OCH MeOCH MeOCH2 CH CHOMe CHOMe CH OHC CC MeOC HH H H OMeOC MeOCH H H H COOMe C H C AcNMeC C H O CH2H OMe MeOCH MeOCH2 659.3 OC MeOCH H H H COOMe C H C AcNMeC C H O 659.3 H OMe 659.3 NeuAcHexHexNAcitol + Na+ 30
  • 31. LINKAGE ANALYSIS 45  GC/EI-MS analysis – Spectrum of 1,2-linked Mannose LINKAGE ANALYSIS OAc OAc CH3O CH2OCH3 H 45 H OAc CH2OCH3 117 161 306 129OAc OCH3 OAc D H OCH3 H OCH3 161 205 190 234129 130 129 130 CHDOAc H OAc 277 74 146 161 74 190 161 190 31
  • 32. LINKAGE ANALYSIS 73  GC/EI-MS analysis – spectrum of 1,3,6-linked Mannose LINKAGE ANALYSIS OA CH2OAc 73 H OAc CH2OAc 145 189 306 129 OAc OAc CH3O H D H OAc H OCH3 189 261 190 234 118 129 OAc OCH3 CHDOAc H OCH3 305 74 118 129 74 234 189 32
  • 33. LINKAGE ANALYSIS 45  GC/EI-MS analysis – spectrum of 1,4-linked N-Acetylglucosamine LINKAGE ANALYSIS OAc OAc AcO CH2OCH3 H 45 H OAc CH2OCH3 117 189 347 OAc OCH3 NCH3Ac D OCH3H H OAc 189 233 203 275117 CHDOAc H NCH3Ac305 74 159117 74 159 233 33
  • 34. LINKAGE ANALYSISLINKAGE ANALYSIS 100 16.752 117+118+129+159 3.33e6 RT 4-GlcNAc % 6 G l 14.001 t-Gal 2-Man 3-Gal 6-Gal 2,4-Man 4,6-GlcNAc 10.000 11.000 12.000 13.000 14.000 15.000 16.000 17.000 18.000 19.000 20.000 rt0 13.171 13.471 14.941 t-Gal 3,6-Man , 34
  • 35. STEREOSPECIFICITY OF LINKAGE 3363.3 90 100 Voyager Spec #1=>SM3=>AdvBC(32,0.5,0.1)[BP = 2041.4, 4588] 681.5 Mixture of Gal1-3Gal1-4Gal1-3Gal (Mass 885Da) and Gal1-4GlcNAc1-3Gal1-4Glc (Mass 926 Da) Incubated with -Galactosidase 681.5 50 60 70 80 %Intensity 926.7 926.7 00 10 20 30 40 % 599.0 719.2 839.4 959.6 1079.8 1200.0 Mass (m/z) 00 2728 6100 Voyager Spec #1=>SM3=>AdvBC(32,0.5,0.1)[BP = 1836.2, 4445] 885.5722 4 Mixture of Gal1-3Gal1-4Gal1-3Gal (Mass 885 Da) and Gal1-4GlcNAc1-3Gal1-4Glc (Mass 926 Da)885.5722 5 2728.6 60 70 80 90 100 722.4 and Gal1 4GlcNAc1 3Gal1 4Glc (Mass 926 Da) Incubated with -Galactosidase 885.5722.5 20 30 40 50 %Intensity 35 599.0 719.2 839.4 959.6 1079.8 1200.0 Mass (m/z) 00 10
  • 36. 2 AB STACKED CHROMATOGRAMS2-AB STACKED CHROMATOGRAMS Five separate Mab N glycan preparationsFive separate Mab N-glycan preparations G0F G1F G2F Run 1 0.59 0.32 0.09 Run 2 0.58 0.32 0.09 Run 3 0.59 0.32 0.09 Run 4 0.58 0.33 0.09 Run 5 0 58 0 32 0 09Run 5 0.58 0.32 0.09 Average 0.584 0.322 0.09 SD 0.0055 0.0045 0.00 %CV 0.94 1.40 0.00 36
  • 37. 2 AB STACKED CHROMATOGRAMS2-AB STACKED CHROMATOGRAMS Diff i t f M b tiDiffering amounts of Mab preparations 100μg 10μg 50μg 37
  • 38. TAKE HOME MESSAGESTAKE HOME MESSAGES  Mass spectrometric analysis provides detailed structural information on composition, antennal structures and linkage.  Chromatography provides a unique glycan profile due to the precise structure and associated interactions of the glycans with the column t i Thi fil b d f i t hi h thmatrix. This profile can be used as a reference against which other batches can be compared. Useful for characterisation, stability, forced degradation studies.  The use of LC/ES-MS of proteolytic digests allows sites of glycosylation to be isolated and identified. These sites can then be analysed using the b t h i t d t i th t f th l t h itabove techniques to determine the nature of the glycans at each site. 38
  • 39. CARBOHYDRATES MAKE IT ON TV!CARBOHYDRATES MAKE IT ON TV! 39
  • 40. THANK YOU FOR YOUR ATTENTIONTHANK YOU FOR YOUR ATTENTION Life Science Services Dr Andrew J Reason Group Manager SGS M-Scan Europe SGS M Scan Ltd Phone: +44 (0) 118 989 6940 Life Science Services Dr Richard Easton Team Leader, Carbohydrate Analysis SGS M S Ltd Ph 44 (0) 118 912 1190 + 41 22 739 9548 SGS M-Scan Ltd Phone: +44 (0) 118 989 6940 2-3 Millars Business Centre, Fax: +44 (0) 118 989 6941 Fishponds Close, E-mail : andrew.reason@sgs.com Wokingham Berkshire, RG41 2TZ, UK Web : www.sgs.com/biopharma SGS M-Scan Ltd Phone: +44 (0) 118 912 1190 2-3 Millars Business Centre, Fax: +44 (0) 118 912 1191 Fishponds Close, E-mail : uk.biopharma@sgs.com Wokingham E-mail : richard.easton@sgs.com Berkshire, RG41 2TZ, UK Web : www.sgs.com/biopharma + 1 866 SGS 5003 + 65 637 90 111 + 33 1 41 24 87 87 + 1 877 677 2667 40 1 877 677 2667